Biotech · Private company
Idera Pharmaceuticals, Inc.
Track this companyFree. Adds Idera Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- IpilimumabPhase 3 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Tilsotolimod with IpilimumabPhase 3 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IMO-2125Phase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IMO-8400Phase 2 · Waldenstrom's MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- IMO-8400 Dose Group 1Phase 2 · DermatomyositisClinicalTrials.gov · fetched Nov 12, 2026
- IMO-8400 Dose Group 2Phase 2 · DermatomyositisClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- TilsotolimodPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- IMO-2125Phase 1 · Refractory Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IMO-2125Phase 1 · Hepatitis CClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPHASE1 · COMPLETED · started Jan 22, 2020ClinicalTrials.gov NCT04196283 · fetched Nov 12, 2026
- Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 29, 2019ClinicalTrials.gov NCT03865082 · fetched Nov 12, 2026
- A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaPHASE3 · TERMINATED · started May 30, 2018ClinicalTrials.gov NCT03445533 · fetched Nov 12, 2026
- A Study of Intratumoral IMO-2125 in Patients With Refractory Solid TumorsPHASE1 · COMPLETED · started Jun 9, 2017ClinicalTrials.gov NCT03052205 · fetched Nov 12, 2026
- A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic MelanomaPHASE2 · COMPLETED · started Dec 1, 2015ClinicalTrials.gov NCT02644967 · fetched Nov 12, 2026
- Trial of IMO-8400 in Adult Patients With DermatomyositisPHASE2 · COMPLETED · started Nov 1, 2015ClinicalTrials.gov NCT02612857 · fetched Nov 12, 2026
- Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's MacroglobulinemiaPHASE1_PHASE2 · TERMINATED · started Mar 1, 2014ClinicalTrials.gov NCT02092909 · fetched Nov 12, 2026
- Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected PatientsPHASE1 · COMPLETED · started Sep 1, 2007ClinicalTrials.gov NCT00728936 · fetched Nov 12, 2026